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ABSTRACT
Objective: To perform a systematic literature review of
the long-term safety of methotrexate (MTX) monotherapy
in rheumatoid arthritis (RA).
Methods: A search was performed in Medline, Cochrane
and EMBASE. Adults with RA who had received MTX
monotherapy for more than 2 years were studied.
Results: 88 published studies were included. Over 12
years of treatment, the termination rate of MTX due to
toxicity was less than for sulfasalazine, gold, D-
penicillamine and higher than for hydroxychloroquine (level
of evidence 2a–2b). Long-term use of MTX does not
appear to be a risk factor for serious infections, including
herpes zoster (2b–4), and could provide a survival benefit
by reducing cardiovascular mortality (2b). The prevalence
of raised liver enzymes (more than twice the upper limit of
normal) is close to 13% of patients; 3.7% of patients
stopped MTX permanently owing to liver toxicity (2b).
Data on the risk for liver fibrosis/cirrhosis are conflicting: a
meta-analysis showed an incidence of fibrosis of 2.7%
after 4 years of MTX (2a). However, two other studies on
sequential liver biopsies did not show evidence for
developing severe damage (2b). Insufficient data are
available to fully assess the risk of lymphoma and
malignancies, although there is no strong evidence of
increased risk (2b–4).
Conclusion: This systematic literature search on MTX
monotherapy with relatively low-dose use during at least
2 years shows favourable long-term safety.
Rheumatoid arthritis (RA) is a systemic autoim-
mune disorder characterised by a chronic poly-
articular synovial inflammation that may lead to
irreversible joint damage with disability and
deformity. The conventional treatment of RA
combines corticosteroids and disease-modifying
antirheumatic drugs (DMARDs), in particular,
methotrexate (MTX). In the management of early
and established RA, MTX is recommended as a
first-line drug by the European League Against
Rheumatism (EULAR) and the American College
of Rheumatology (ACR).
12This drug inhibits the
metabolism of folic acid, has a hepatic metabolism
and a renal excretion. As an antimetabolic agent,
MTX may cause adverse events such as cytopenia,
serious infections, liver damage and mucocuta-
neous problems. Hypersensitivity pneumonitis
may also occur during MTX therapy. If MTX is
effective, patients usually receive several years of
treatment and therefore knowledge about long-
term safety is of major importance.
This manuscript is part of the multinational 3E
Initiative (Evidence, Expertise, Exchange) to
develop recommendations for the management of
rheumatic diseases. More background information
on this 3E Initiative and the resulting evidence-
based recommendations on the use of MTX are
published in this issue of the journal.
3 This paper
describes the literature review to answer the
question: ‘‘What is the long-term safety of
methotrexate, including cardiovascular diseases,
malignancies, infections and liver toxicity?’’.
METHODS
Systematic literature search
To summarise the published evidence for the
long-term safety of MTX in patients with RA a
systematic literature search was performed. The
process of the search, described step by step is
provided as supplemental material on the web-
site (http://www.annrheumdis.com/supplemental,
table 1w). The most important decisions were
to define long term as more than 2 years, to
focus on patients with RA, treated with MTX as
monotherapy.
Thereafter, we selected the relevant key words in
Medline with the help of a librarian, defining the
exact population, intervention and control groups
as well as the outcomes. Several combinations of
key-words (supplemental table 2w, online only)
were used to search in Medline, EMBASE and
Cochrane Central (without limitation in time,
journal or languages). We completed this search
with the ACR and EULAR abstracts of the past 3
years (2005–7). The search was performed on
studies published until October 2007. Using pre-
defined inclusion and exclusion criteria, we
screened all the references obtained in the three
databases. The selection was initially made using
the titles and the abstracts, then for the remaining
studies by reading the complete paper. This search
in each database and the screening was performed
twice by the same person (CS).
The next step was the assessment of the level of
evidence of each of the included studies, using the
evidence-based medicine levels of evidence
(Oxford, May 2001, http://www.cebm.net
(accessed 21 April 2008). This five-level scale
classifies the level of evidence according to the
study design with 1 as the highest level of evidence
(supplemental table 1w, online only).
Data extraction and analysis
For each included study, the study design, quality
usingtheOxford scale,numberofincluded patients,
definition of comparator groups, duration of use
and mean dose of MTX, duration of follow-up as
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(RR) or odds ratio), incidence rate (IR) or standardised mortality
rate have been described. When appropriate, we also pooled the
results of the prospective cohort studies for each type of adverse
event. The pooled results provided in this review are expressed as
percentages of patients experiencing a particular adverse event
and have been calculated as (number of new adverse events/
number of patients at risk during the follow-up)6100. The data
were not sufficiently detailed to be able to calculate the events
per patient per year of follow-up.
RESULTS
Results of the literature search
We obtained 2574 abstracts. Based on titles and abstracts and,
for some of the papers, by reviewing the full paper, we excluded
2490 published studies consistent with our predefined inclusion
and exclusion criteria. The details of the selection process and
the reasons for exclusion appear for each database in the flow
chart (fig 1, online only).
Finally, 88 published studies and three congress abstracts (all
references are listed in the online supplemental data available at
http://www.annrheumdis.com/supplemental) were included
for the analysis. They contain data on mortality, general
toxicity, infections, cardiovascular diseases, liver toxicity,
malignancies, cytopenia and pulmonary involvement. No
randomised controlled trial could be included because of the
,2 years’ duration of MTX treatment in randomised controlled
trials. Table 3w (online only) provides the number of studies for
each topic in detail, grouped according to the study design. We
included two meta-analyses, 54 prospective studies and three
case–control studies in our review.
Toxicity in general
Termination rates for toxicity
During up to 12.7 years of treatment, the rates of discontinua-
tion for toxicity in the MTX groups presented as the range of
the various studies (10–37%) were less than for sulfasalazine
treatment (17–52%), D-penicillamine (24–55%) and gold (22–
64%) treatments, but higher than for hydroxychloroquine
(HCQ) (10–14%) (table 4w, online only).
Adverse events
To examine the adverse events in patients receiving MTX, we
retained and pooled the results from the 21 prospective studies
presenting the number of adverse events (table 1).
4–24 Thus,
among 3463 patients with RA who received on average a low
dose of MTX (8.8 mg/week) for a mean duration of
36.5 months, 72.9% of patients had at least one adverse event.
The most common adverse events were gastrointestinal and
elevation of liver enzymes.
Kremer et al performed a long observational study (up to
104 months, mean doses of MTX between 12.4 and 14.6 mg/
week) in a small number of patients (level of evidence 2b).
21–23 25
At baseline, 29 patients were included and after 79 months, 20
remained in the study. The prevalence of patients who
experienced side effects after 2 years of treatment was 79–85%
and constant over time (up to 104 months). Gastrointestinal
adverse events were the most common side effect (52–65%) and
had similar incidence whatever the duration of MTX. Elevations
of liver enzymes (above the upper limit of normal) occurred
especially during the first 4 years of treatment (69–88%) and
then decreased (25% then 15% after 79 months). The number of
neurological events (headache, light headedness, fatigue, ver-
tigo, feeling ‘‘out of sorts’’, 21–38%) and leukopenia (20–25%)
also remained constant over time. Four withdrawals occurred
before 53 months of treatment.
Using the ARAMIS data bank (Arthritis Rheumatism and
Aging Medical Information System), Fries et al compared the
toxicity of commonly used DMARDs in RA (level 2b).
26 They
used a toxicity index computed from clinical symptoms,
laboratory abnormalities and hospitalisations reported by
patients, health professionals and doctors.
27 According to this
score, HCQ was statistically less toxic than all other DMARDs,
while auranofin was the most toxic. HCQ was followed
by intramuscular gold and as one group closely together
D-penicillamine, MTX and azathioprine. This toxicity score is
not usually routinely used probably because of it complexity.
Methotrexate pneumonitis
According to the results from the 21 prospective studies, only 15
cases of MTX pneumonitis occurred among the 3463 patients
with RA receiving MTX (0.43%) up to 36.5 months (table 1).
MTX pneumonitis, considered as an acute hypersensitivity
reaction, occurs early in the course of MTX, thus it does not
seem to be a problem of long-term treatment by MTX.
Cytopenia relative to long-term MTX treatment
Table 1 also shows data on cytopenia: 179 events of cytopenia
in one cell line (5.2%) occurred in patients with RA receiving
MTX up to 36.5 months. The rate of thrombopenia was 4.1% in
a retrospective study.
28 Pancytopenia seems to be less common
with an incidence of 0.96–1.4% in a few retrospective studies
(level 4).
29
Mortality in patients with RA who received long-term MTX
Table 5w (online only) gives details of the active cohort. The
mortality IR of the MTX group (23 per 1000 person-years) was
Table 1 Most common adverse events (AEs) attributed to methotrexate (MTX) and permanent discontinuation due to toxicity in patients with
rheumatoid arthritis (RA): pooled results from 21 prospective cohorts (level of evidence 2b)
4–24
Patients
Mean dose of
MTX
(mg/week)
Mean
duration of
MTX
(months)
Number of
all AEs
Permanent
discontinuation
Gastro-
intestinal Liver Skin/hair
Central
nervous
system Cytopenia Lung
Number 3463 8.8 36.5 2524 315/3007* 1065 640 309 191 179 84 (15{)
Range 24–1155 4.6–18 27–132 22–475 10–257 0–122 0–111 0–58 0–27 0–28
% 72.9 10.5 30.8 18.5 8.9 5.5 5.2 2.4 (0.43){
*Total number of patients in studies with data available concerning permanent discontinuation of MTX.
Gastrointestinal (GI): stomatitis, ulcer, abdominal pain, GI bleed, dyspepsia, nausea, vomiting, diarrhoea, weigh loss, appetite loss; liver toxicity: increase of aspartate
aminotransferase and/or alanine aminotransferase upper limit of normal; skin/hair: ulcer, pruritis, skin rash, alopecia, skin itching, moon face, eczema; central nervous system:
headache, depression, blurred vision, transient ischemic attack, stroke, vertigo, lethargy, malaise, fatigue; cytopenia: haemoglobin decreased .2 gm/dl or platelets ,150 000/mm
3,
white blood cells ,3500/mm
3; lung: MTX pneumonitis ({), pulmonary dysfunction, cough and unspecified pulmonary adverse drug reactions.
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1000 person-years). Moreover, MTX may provide a survival
benefit by reducing cardiovascular mortality in comparison
with patients with RA treated with other DMARDs (adjusted
hazard ratio of cardiovascular mortality 0.3 (95% CI 0.2 to 0.7).
However, in the retrospective cohort the RR for mortality was
3.4 in patients with RA with a history of cardiovascular diseases
(CVD) starting MTX as compared with patients with RA
without CVD who started MTX and patients who started other
DMARDs and patients with CVD but not receiving MTX.
Risk of CVDs in patients with RA who received long-term MTX
Two case–control studies were included to estimate the risk of
CVD during MTX treatment (table 5w, online only). One study
concluded that MTX is not a risk factor for CVD in patients
with RA and the second study even found a reduced risk
compared with patients with RA who never received MTX,
sulfasalazine or HCQ.
Infections in patients with RA receiving long-term of MTX
Table 5w (online only) summarises six studies included in the
analyses. Over 3 years of treatment, 8.3% of patients had serious
infections, and a large majority of infections (79%) occurred
during the first 2 years of treatment. According to the studies
included, MTX does not seem to be associated with a higher risk
for infections, in general, or serious infections, including herpes
zoster and infectious complications, after total hip or knee
replacements.
Lymphoma and malignancies
Overall, patients with RA have an increased risk of lymphoma
in comparison with the general population, which is mainly
related to high levels of disease activity.
30 A relationship
between MTX treatment and the occurrence of lympho-
proliferative disorders (LPDs) in RA has been topic of discussion
for many years. MTX could be associated with Epstein–Barr
virus-related LPD and patients with spontaneous regressions of
LPD after MTX withdrawal have been described.
31
The studies included in this review did not allow us to assess
fully the risk of long-term MTX treatment on the occurrence of
lymphoma and malignancies in patients with RA, although
there does not seem to be an indication of an increased risk
(table 5w, online only).
For the risk of lymphoma, most of the studies compared
MTX groups with the general population and not with patients
with RA who did not receive MTX. Wolfe’s study is the only
study providing the incidence rates of lymphoma in patients
with RA with and without MTX. In the MTX group, this rate is
higher than in the ‘‘no MTX, no biological agent’’ group.
Unfortunately, no adjustment on RA severity was performed.
Thus this higher incidence might be due to a higher severity of
RA in the MTX group and not to the drug effect itself. For other
malignancies, there are no data on the risk of MTX use in
comparison with patients with RA who have received other
DMARDs as a control group.
Liver toxicity in patients with RA who received long-term MTX
Elevation of liver enzymes is the second most common adverse
event during MTX treatment after gastrointestinal side effects
(table 2). To evaluate the incidence of elevation of liver
enzymes, we pooled the results from 27 prospective studies
that evaluated a total of 3808 patients with RA who received a
low dose of MTX (10.5 mg/week) during 55.8 months, on
average.
4–24 32–37 A total of 769 patients had at least one episode
of elevated liver enzymes (20.2%), 12.9% had an elevation up to
two times the upper limit of normal and 3.7% of patients
stopped MTX because of liver toxicity.
Liver damage evaluated on liver biopsy
One meta-analysis (table 6w, online only) provides the results
of sequential liver biopsies performed systematically in patients
receiving MTX. These results have to be judged with caution
because these studies were all uncontrolled and some do not
report baseline biopsy results. The meta-analysis suggests that
3% of patients would develop severe fibrosis or cirrhosis over
55 months’ treatment with MTX, especially if they drink at
least 100 g of alcohol a week (corresponding to 10 glasses a
week).
In the two studies with baseline biopsies, not a single patient
had evidence of severe fibrosis or cirrhosis after 4 years of
treatment (cumulative dose of MTX around 2000 mg).
21 38
DISCUSSION
To date, this is the first review that specifically deals with the
long-term safety of MTX monotherapy in patients with RA.
According to the cohort and case–control studies, there is no
evidence of an increased risk of CVD, mortality and infections
in patients receiving MTX. Overall, although many patients
experience adverse events during MTX treatment, they are
generally mild and withdrawals of MTX for toxicity are less
common than for most other DMARDs. The results remain
inconclusive for the risk of cirrhosis and malignancies, including
lymphoma.
There are challenges to the interpretation of the data as
several weaknesses were apparent in the results of the
systematic literature search. First, the studies were heteroge-
neous in their study design, the level of evidence, the type of
adverse events reported, the presentation of the results as
prevalence, incidence rate, RR, etc. Moreover, the control
groups were not always well defined and described. Also,
information on relevant data such as comorbidity, concomitant
use of other drugs and folic acid supplementation were often
not available. Consequently, we could only pool the results for
the adverse events in general and elevation of liver enzymes
from uncontrolled prospective studies. But even here, we were
unable to present the occurrence of adverse events per patient
per year of exposure.
Table 2 Elevation of liver enzymes during methotrexate (MTX) treatment: pooled results of 27 prospective
studies
4–24 35–40 (level 2b)
Number of
patients
Mean dose of
MTX (mg/week)
Mean duration
(months)
Abnormally high
ALT or AST
ALT or AST
.2 ULN
Permanent
discontinuation
3808 (16–1155) 10.5 (4.6–18) 55.8 (27–180) 769 (20.2%) 114/883* (12.9%) 66/1799* (3.7%)
Results are shown as number (%) or number (range).
*Total number of patients in studies with data available concerning permanent discontinuation of MTX.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.
Extended report
1102 Ann Rheum Dis 2009;68:1100–1104. doi:10.1136/ard.2008.093690Second, the focus of the systematic literature search is on use
of MTX as monotherapy. This is valid but does limit the
interpretation on the long-term safety of MTX in combination
with other DMARDs and/or biological agents which is often the
case in modern treatment of RA.
Third, the average dose of 10.7 mg/week overall in all studies,
with a maximum dose of 18 mg/week in one study, is low
compared with the currently recommended dose. We tried to
evaluate a time trend in the dosage of MTX use but the mean
dose in the studies published before 1995 was similar to the dose
used in the studies published after 1995. Recent publications do
include data on the use of MTX in higher dosages, but there is
only information on long-term safety in one of these studies.
39
However, this study shows no difference in frequency and type
of adverse events from those in the studies with lower dosages.
But in general, the data provided in this systematic literature
search relate to the long-term safety of relatively low doses of
MTX.
Fourth, nowadays concomitant use of folic acid and MTX is
standard treatment. Most of the studies did not report or
insufficiently reported the use of folic acid. Therefore, we do not
know what the role of folic acid is in the long-term safety of
MTX. However, within the 3E Initiative there is a specific
systematic literature search on the usefulness of adding folic
acid to MTX.
40
Although the data on cirrhosis and malignancies are incon-
clusive, the findings of this review do not suggest serious
problems of toxicity with the long-term use of MTX as
monotherapy with an average dose of 10.7 mg/week in patients
with RA. Many patients experience adverse events, but these
are usually of mild. Whether these conclusions are valid for
higher doses and in combination with other DMARDs and
biological agents needs to be investigated by future research.
The data from this systematic literature search were used as one
of the evidence-based pieces of information forming the basis
for the recommendations on the use of MTX in rheumatic
diseases.
3
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